FDA notifications.  Raltegravir indication extended for treatment-naive patients.
D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004348:Drug Labeling; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011760:Pyrrolidinones / Q000009:adverse effects / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D014481:United States; D014486:United States Food and Drug Administration
D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium